United States: FDA Issues Revised Draft Reprints Guidance

On February 28, 2014, the Food and Drug Administration ("FDA") released a revised draft guidance for industry entitled "Distributing Scientific and Medical Publications on Unapproved New Uses–Recommended Practices" ("Revised Reprints Guidance"). In the March 3, 2014, Federal Register notice announcing the availability of the Revised Reprints Guidance, FDA noted that comments are due on May 2, 2014.

The Revised Reprints Guidance proposes changes to FDA's January 2009 final guidance"Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices." ("2009 Guidance"). Both the 2009 Guidance and its new revision address the practices a manufacturer should follow when distributing scientific and medical publications to health care professionals that include information on unapproved new uses (i.e., "off-label uses") for an approved or cleared product. While many of the concepts set forth in the 2009 Guidance remain as to journal reprints, the Revised Reprints Guidance provides distinct treatment for dissemination of reference texts and, importantly, adds specific recommendations for the distribution of "clinical practice guidelines ("CPGs"),[1] which were not addressed at all in the 2009 Guidance. 

FDA explicitly indicated that the Revised Reprints Guidance is in direct response to two pending citizen petitions[2] filed by members of the Medical Information Working Group (MIWG), an ad hoc coalition of drug and device manufacturers to which Ropes & Gray LLP serves as one of the outside counsel. Further, as discussed below, FDA's Federal Register notice states that the agency will continue to address other requests set forth in the MIWG's citizen petitions.

I. Key Changes in the Revised Reprints Guidance

While the Revised Reprints Guidance indicates some additional regulatory flexibility by permitting the distribution of CPGs, other key changes suggest that FDA is looking to restrict certain reprint distribution practices. Below we describe the important features of the Revised Reprints Guidance.

  • Allowance of CPG Distribution: In contrast to the 2009 Guidance, which is silent on the subject, the Revised Reprints Guidance expressly allows manufacturers to distribute CPGs that include information on off-label uses for approved or cleared products. FDA would allow distribution of only those CPGs that incorporate the Institute of Medicine's (IOM's) standards for "trustworthiness"[3] and thus are aimed at ensuring that CPGs are informed by a "systematic review of evidence" and an assessment of the benefits and risks of "alternative care options." Like the requirements for other scientific and medical publications from the 2009 Guidance, CPGs would have to be accompanied by standard disclaimers as to risks of off-label uses, along with financial disclosures related to any of the CPG authors, and relevant context and bibliographic information.
  • Distribution of CPGs and Reference Texts in Their Entirety or Individual Sections: While the Revised Reprints Guidance retains the requirement that a journal article should be distributed only in an "unabridged" form, it expressly allows the distribution of CPGs and reference texts either in their entirety or in individual sections (e.g., chapters) that include information on unapproved uses. If a manufacturer chooses to distribute an individual section of a text or CPG, it must be the complete, unabridged section. Further, the Revised Reprints Guidance provides that a CPG addressing one disease state, rather than multiple disease states, should be disseminated only in its entirety.
  • Meta-Analysis and Non-Clinical Research Information Limited to Medical Device Reprints: The 2009 Guidance permits distribution of reprints and texts that "address adequate and well-controlled clinical investigations," including historically controlled studies, pharmacokinetic ("PK") and pharmacodynamic ("PD") studies and meta-analyses of a specific clinical hypothesis, without any distinction between medical device and drug reprint practices. The Revised Reprints Guidance draws such a distinction. Drug reprints are limited to information that addresses adequate and well-controlled studies, whereas device reprints also can discuss "significant investigations other than adequate and well-controlled studies, such as meta-analyses, if they are testing a specific clinical hypothesis" and "significant non-clinical research (such as well-designed bench or animal studies)." As currently written, the Revised Reprints Guidance implies that drug manufacturers cannot distribute reprints discussing meta-analyses, PK or PD studies and other significant non-clinical research.

II. Impact of MIWG Petitions on FDA's Regulation of Manufacturer Communications

In addition to announcing the availability of the Revised Reprints Guidance, FDA's Federal Register notice explains that the agency is continuing to consider the specific requests set forth in the MIWG's pending citizen petitions. Specifically, in July 2011, seven MIWG member companies filed a citizen petition requesting FDA to clarify its regulatory approach to four types of manufacturer communications about off-label uses: (1) responses to unsolicited requests; (2) scientific exchange; (3) communications with formulary committees and payors; and (4) the dissemination of third-party CPGs. In response, on December 28, 2011, FDA issued a draft guidance entitled"Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices"  and opened a public docket on the concept of "scientific exchange." In September 2013, MIWG filed a second citizen petition requesting FDA to respond fully to all four requests in the July 2011 petition and further requesting FDA to undertake a comprehensive review and modification of its entire regulatory approach to manufacturer communications, particularly in light of three recent cases[4] highlighting the constitutional and statutory limitations of FDA's regulatory authority.

The Federal Register notice acknowledged that the agency has not yet reached a final determination on the issues presented in the MIWG's citizen petitions. But the notice indicated FDA intends to address a number of those issues. For example, the Federal Register notice explicitly lays out FDA's responses to-date regarding some of the issues raised in MIWG's citizen petitions, including (1) creating a public docket to solicit public input on the concept of scientific exchange; (2) considering comments on the 2011 unsolicited requests draft guidance and (3) considering draft guidance on industry interactions with formulary committees and payors, including presentation of health care economic information. Both the notice and the Revised Reprints Guidance, however, were silent on recent First Amendment case law and its potential impact on FDA regulation. 

It remains to be seen whether any regulatory changes made by FDA will result in additional flexibility or additional scrutiny over manufacturer communications regarding truthful, non-misleading information about unapproved uses for approved or cleared products.


[1] The Revised Reprints Guidance defines CPGs as statements that include recommendations intended to help clinicians make decisions for individual patient care, including in circumstances where there are few or no approved drugs or devices indicated for the patient's condition or the approved therapies have not proven successful for the individual."

[2] See July 2011 Citizen Petition FDA-2011-P-0512; September 2013 Citizen Petition FDA-2013-P- 1079.

[3] FDA clarifies that standards for CPG "trustworthiness," incorporated in the Revised Reprints Guidance, are taken directly from IOM's Congressionally mandated study that focused on "the best methods used in developing clinical practice guidelines in order to ensure that organizations developing such guidelines have information on approaches that are objective, scientifically valid, and consistent," results of which are set forth in its report, Robin Graham, et al., Institute of Medicine of the National Academies, Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Clinical Practice Guidelines We Can Trust (2011).

[4] See Sorrell v. IMS Health, Inc.,131 S. Ct. 2653 (2011); FCC v. Fox Television Stations, 132 S. Ct. 2307 (2012); United States v. Caronia, 703 F.3d 149 (2d Cir. 2012).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.